Performance of a second-generation methylated SEPT9 test in detecting colorectal neoplasm.

There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.

Abstract

Screening and early detection reduces mortality due to colorectal cancer (CRC). Methylated Septin 9 (SEPT9) is a new blood-based biomarker for CRC. We evaluated the performance of the second-generation SEPT9 assay for the detection of colorectal neoplasm, and compared it with fecal immunochemical test (FIT).

Related collections

Author and article information

Journal

Journal ID (iso-abbrev): J. Gastroenterol. Hepatol.

Title: Journal of gastroenterology and hepatology

ISSN (Electronic): 1440-1746

ISSN (Print): 0815-9319

Publication date (Electronic): May 2015

Volume: 30

Issue: 5

Affiliations

[1 ] Third Military Medical University, Chongqing, China; Department of Gastroenterology, Beijing Military General Hospital, Beijing, China.

Article

DOI: 10.1111/jgh.12855

PubMed ID: 25471329

SO-VID: 0038cc89-ed8b-4280-b373-420661fcc907

History

Keywords: Septin 9,adenoma,colorectal cancer,screening

Data availability:

Keywords: Septin 9, adenoma, colorectal cancer, screening

Comments

Comment on this article

scite_

Cited by 56

See all cited by